Maxim Group Maintains Buy Rating on Scienture Holdings, Lowers Price Target

Scienture Holdings Issues Shareholder Letter Highlighting Financial and Commercial Progress

Scienture Holdings, Inc. released a letter to shareholders detailing a 256% sequential revenue growth for the first nine months of 2026 and progress toward 2027 profitability.

8-K filing — Scienture Holdings, Inc. (SCNX)

Filed: 2026-10-19 AccNo: 0001493152-26-047579 Size: 269 KB Item 2.02: Results of Operations and Financial Condition Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 9.01: Financial Statements and Exhibits

Scienture Holding shares are trading lower despite reporting preliminary Q3 revenue of $1.22 million, up 256% sequentially.

SCIENTURE HOLDINGS Reports Preliminary Q3 Revenue Of ~$1.22M

SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers

EXCLUSIVE: Scienture Reports Preliminary Q3 Sales of ~$1.22M, Sequential Growth of 256%, Arbli Wholesale Unit Sales Increased 74% Sequentially

EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability

Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.